Regulation of AMPK/PPARα/SCAD signal pathway on cardiac hypertrophy

AIM：To study the effect of short-chain acyl-coenzyme A dehydrogenase (SCAD）on cardiac hypertrophy and to explore the role of adenosine monophosphate-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor α (PPARα） signal pathway in the regulation of SCAD during the development of cardiac hypertrophy. METHODS：The optimal sequence of SCAD interference was chosen by Western blotting and real-time PCR. The cardiomyocytes were treated with fenofibrate (10 μmol/L) for 24 h and subsequently stimulated with the optimal sequence of SCAD interference. The changes of SCAD expression at mRNA and protein levels, the enzyme activity of SCAD, the cardiomyocyte surface area and free fatty acids were determined. Using real-time PCR for analyzing the markers of cardiac hypertrophy, the mRNA expression of atrial natriuretic factor (ANF） and brain natriuretic peptide (BNP) was detected to judge the development of cardiac hypertrophy. The cardiomyocytes were treated with fenofibrate (10 μmol/L) or AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR, 0.5 mmol/L) for 30 min and subsequently stimulated with phenylephrine (PE, 20 μmol/L) for 24 h. The changes of cardiomyocyte surface area, free fatty acids, and the expression of SCAD, PPARα and p-AMPKα (T172) at mRNA and protein levels were observed. RESULTS：The effect of optimal sequence siRNA-1186 and PE on the cardiomyocytes was the same. Compared with control group, the expression of ANF and BNP at mRNA level, the cardiomyocyte surface area and free fatty acids were increased obviously in siRNA-1186 group. After pretreated with fenofibrate (10 μmol/L), the expression of PPARα and SCAD, and the enzyme activity of SCAD were significantly increased, while the free fatty acids were decreased, indicating that fenofibrate prevented the development of cardiac hypertrophy induced by knockdown of SCAD. Compared with control group, the expression of SCAD, PPARα and p-AMPKα (T172) at mRNA and protein levels was significantly down-regulated, and the enzyme activity of SCAD was obviously decreased in PE group. Compared with PE group, the expression of SCAD, PPARα and p-AMPKα (T172) was significantly up-regulated, and the cardiomyocyte surface area and the content of free fatty acids were obviously decreased in the cardiomyocytes pretreated with fenofibrate or AICAR for 30 min. CONCLUSION：Down-regulation of SCAD is related to the cardiac hypertrophy and energy metabolism. AMPK/PPARα/SCAD signaling pathway may regulate cardiac hypertrophy directly.     

Expression of short-chain acyl-CoA dehydrogenase during heart development in rats and relationship with cardiac hypertrophy

AIM： To investigate the expression of short-chain acyl-CoA dehydrogenase during the heart deve-lopment in rats and to analyze the relationship between short-chain acyl-CoA dehydrogenase and cardiac hypertrophy in spontaneously hypertensive rats (SHR). METHODS：The expression and activity of short-chain acyl-CoA dehydrogenase in the hearts of Wistar rats with different ages were measured. Free fatty acids in serum and cardiac muscles were also determined. RESULTS：Compared with the fetal rats of 19 d, the expression and activity of short-chain acyl-CoA dehydrogenase in the postnatal rats of 1 d, 2 weeks, 6 weeks and 16 weeks were increased, and free fatty acids in the serum and myocardium were obviously decreased. The difference began in evidence from the age of 2 weeks. The expression of short-chain acyl-CoA dehydrogenase was significantly up-regulated with negative correlation to free fatty acids in the serum and myocardium during heart development. Systolic blood pressure was similar in 2-week-old SHR and WKY rats, which significantly increased in SHR of 6 weeks and 16 weeks old compared with the age-matched WKY rats. The ratio of left ventricular weight to body weight was markedly elevated in SHR of 2 weeks, 6 weeks and 16 weeks old compared with the age-matched WKY rats, indicating that the appearance of cardiac hypertrophy occurred before the development of hypertension in SHR. Compared with the age-matched WKY rats, the expression and activity of short-chain acyl-CoA dehydrogenase were decreased and free fatty acids in the serum and myocardium were obviously higher in SHR. The expression of short-chain acyl-CoA dehydrogenase was significantly down-regulated with a negative correlation to free fatty acids in the serum and myocardium of SHR. CONCLUSION：The expression of short-chain acyl-CoA dehydrogenase is increased during the heart development, which may be associated with the increase in cardiac fatty acid utilization. The down-regulated expression of short-chain acyl-CoA dehydrogenase in the hypertrophic heart may be responsible for the recapitulation of fetal energy metabolism.     

Effect of short-chain acyl-CoA dehydrogenase on cardiac hypertrophy induced by hypertension or exercise training

AIM: To investigate the differential expression of short-chain acyl-CoA dehydrogenase (SCAD) in cardiac hypertrophy induced by hypertension or exercise training. METHODS: Spontaneously hypertensive rats (SHR) were used as the model of pathological cardiac hypertrophy. The swim-trained rats were used as the model of physiological cardiac hypertrophy. The systolic pressure, cardiac hypertrophy parameters, echocardiogram parameters, free fatty acid in serum and cardiac muscle, and the expression and activity of SCAD in the left ventricle were measured. RESULTS: Compared with the control rats, trained rats developed an athletic heart, of which cardiac function was enhanced, whereas SHR developed hypertensive cardiac hypertrophy, of which cardiac function was deteriorated. Compared with the control rats, the ratios of left ventricular weight to body weight were both increased in trained rats and SHR, showing that the degrees of cardiac hypertrophy were similar in the 2 models. Compared with the control rats, the decrease of free fatty acid both in serum and myocardium indicated that the fatty acid utilization was increased in the left ventricle of trained rats. Meanwhile, the expression and activity of SCAD in the left ventricle of trained rats were increased. However, free fatty acid both in serum and myocardium were increased, indicating that the fatty acid utilization was decreased in the left ventricle of SHR. Furthermore, SHR had the decreased expression and activity of SCAD in the left ventricle. CONCLUSION: The changes of SCAD are different in cardiac hypertrophy induced by hypertension and exercise training, indicating that SCAD may be used as a molecular marker of physiological and pathological cardiac hypertrophy, and a potential therapeutic target of pathological cardiac hypertrophy.     

Role of PPARα/PGC-1α in doxorubicin induced mouse dilated cardio-myopathy

AIM: To investigate the changes of peroxisome proliferator-activated receptors (PPAR)α/peroxisome proliferator activated receptor coactivator 1 alpha (PGC-1α) in doxorubicin (DOX) induced dilated cardiomyopathy (DCM) and its effect on the energy metabolism and myocardial function in mice. METHODS: Forty mice were randomly divided into 4 groups: control group, DOX group, PPARα inhibitor group and PPARα agonist group. The DCM model was established by injection of DOX. The protein levels of PPARα/PGC-1α were detected. The PPARα inhibitor and PPARα agonist were used 2 weeks beforeinjection of DOX. The contents of adenine acid and phosphocreatine (Pcr) in the mitochondria were measured by high-performance liquid chromatography (HPLC). The ANT activity was analyzed by the atractyloside-inhibitor stop technique. The changes of the echocardiography and hemodynamics were also observed. RESULTS: DOX induced DCM model was successfully established. The protein levels of PPARα and PGC-1α in control group were significantly higher than those in DOX group (P<0.05). Both of the high-energy phosphate contents and the transport activity of ANT were decreased in DOX group (P<0.05), and the hemodynamic parameters were disordered (P<0.01). Compared with DOX group, PPARα inhibitor pre-treatment significantly reduced the PPARα/PGC-1α expression. Meanwhile, high-energy phosphate contents in the mitochondria and the ANT transport activity of the mitochondria decreased, as well as the left ventricular function (P<0.05). On the other hand, PPARα agonist significantly increased the expression of PPARα and PGC-1α, and improved the transport activity of ANT. In addition, the hemodynamic parameters were ameliorated, but the high-energy phosphate contents of the mitochondria did not significantly change. CONCLUSION: PPARα/PGC-1α plays an important role in the regulation of ANT transport activity in dilated cardiomyopathy induced by DOX, and the activation of PPARα/PGC-1α has protective effects on the DCM induced by DOX.     

Activation of macrophage peroxisome proliferator-activated receptor α inhibits macrophage inflammation-induced cardiac fibroblast activation and migration

AIM: To investigate the effect of macrophage peroxisome proliferator-activated receptor α (PPARα) activation on macrophage inflammation-induced activation and migration of cardiac fibroblasts. METHODS: Mouse bone marrow-derived macrophages were treated with vehicle, PPARα agonist WY14643 (10 μmol/L), angiotensin Ⅱ (Ang II; 1 μmol/L) or Ang II+WY14643 for 24 h, and the supernatants were collected as conditioned medium (CM) to stimulate cardiac fibroblasts for additional 24 h. The mRNA levels of PPARα, interleukin-6 (IL-6), IL-1β and tumor necrosis factor-α (TNF-α) in the macrophages as well as fibrotic markers collagen type Ⅰ alpha 2 chain (Col1a2), collagen alpha 1 chain (Col3a1) and actin alpha 2 (Acta2) in the cardiac fibroblasts were detected by RT-qPCR. The protein levels of IL-6 and IL-1β in the macrophages as well as collagen I, collagen III and α-smooth muscle actin (α-SMA; encoded by Acta2 gene) in the cardiac fibroblasts were determined by Western blot. Wound-healing assay was applied to eva-luate the migration ability of cardiac fibroblasts. RESULTS: Ang II significantly increased the mRNA levels of pro-inflammatory factors, such as IL-6, IL-1α and TNF-α, but decreased the mRNA level of PPARα in the macrophages. Administration of PPARα agonist WY14643 dramatically decreased Ang II-induced mRNA levels of IL-6, IL-1β and TNF-α in the macrophages, and significantly decreased Ang II-induced protein expression of IL-6 and pro-IL-1β in the macrophages. The CM from Ang II-treated macrophages significantly up-regulated the mRNA levels of Col1a2, Col3a1 and Acta2 in the cardiac fibroblasts, which were inhibited by the CM from WY14643-treated macrophages. The same results were observed in the protein levels of collagen I, collagen III and α-SMA in the cardiac fibroblasts. Moreover, the CM from Ang II-treated macrophages significantly promoted cardiac fibroblast migration, whereas the CM from WY14643-treated macrophages markedly inhibited macrophage inflammation-induced cardiac fibroblast migration. CONCLUSION: WY14643-activated PPARα inhibits activation and migration of cardiac fibroblasts by attenuating Ang II-induced macrophage inflammatory response.     

Effects of resveratrol on cardiac dysfunction and ASMase-ceramide pathway in type 2 diabetic rats

AIM:To investigate the effects of resveratrol (RSV) on cardiac dysfunction and acid sphingomyelinase (ASMase)-ceramide pathway in diabetic rats. METHODS:Type 2 diabetes mellitus (T2DM) model was established by a high-fat diet combined with STZ intraperitoneac injection (30 mg/kg). SD rats (n=20) were randomly divided into control group, T2DM group; T2DM+RSV group (diabetic rats were given resveratrol at 100 mg·kg·d^-1 by intragastric administration for the treatment) and RSV group (some of control rats were selected to give the same dose of RSV for drug control group). The M-mode Doppler ultrasonography was performed to observe the changes of cardiac function and structure in the rats. The levels of serum glucose, lipid and superoxide dismutase (SOD) activity, malondialdehyde (MDA) content in heart tissues were measured. Oil red O staining and Sirius red staining were performed to observe lipid accumulation and cardiac fibrosis in heart tissues. The cardiac ceramide concentration in diabetic rats was analyzed by high-performance liquid chromatography. The protein expression of ASMase and peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) in the hearts was determined by Western blot. RESULTS:Compared with the control group, the levels of fasting blood glucose, total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) were significantly elevated in T2DM group. The values of ±dp/dt_max, fractional shortening and ejection fraction were declined, and the left ventricle internal dimension at end-systole (LVIDs) and left ventricle internal at end-diastole (LVIDd) were increased. Furthermore, increased MDA content and more lipid accumulation were also observed in diabetic hearts, while the SOD activity, ATP content and PGC-1α expression were reduced in diabetic hearts. However, all these parameters were reversed by addition of RSV, concomitant with decreased ASMase expression and ceramide content. CONCLUSION:RSV dramatically alleviates diabetes-induced cardiac dysfunction and cardiac fibrosis, which may attribute to inhibition of ASMase-ceramide activation.     

Over-expression of PGC-1α reverses mitochondrial function reduction and apoptosis in OGD/R-induced neurons

AIM: To investigate the effect of over-expression of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) on mitochondrial morphology and cell apoptosis in the cortical neurons with oxygen glucose deprivation/reoxygenation (OGD/R). METHODS: The whole gene sequence of PGC-1α was obtained from the cerebral cortex of C57BL/6 mice by RT-PCR and cloned into the eukaryotic expression vector pEGFP-N1. The pEGFP-N1-PGC-1α was identified by PCR, and transfected into cortical neurons. The level of PGC-1α expression was identified by Western blot. The cortical neurons transfected with pEGFP-N1 and pEGFP-N1-PGC-1α vectors were treated with OGD/R. The mitochondrial mass, reactive oxygen species (ROS) and ATP production, cell apoptosis and changes of cleaved caspase-3 were detected by MitoTracker Red staining, flow cytometry, ATP metabolic assay kit and TUNEL. RESULTS: Over-expression of PGC-1α inhibited the decrease in mitochondrial biogenesis capacity and the ROS formation of OGD/R neurons (P<0.05), enhanced the ability of ATP synthesis (P<0.01), inhibited neuronal apoptosis (P<0.01) and decreased the activation of caspase-3 (P<0.01). CONCLUSION: PGC-1α over-expression inhibits neuronal apoptosis with OGD/R treatment by promoting mitochondrial biogenesis, inhibiting the production of ROS and maintaining mitochondrial function. PGC-1α may be used as a target for the development of cerebral ischemia/reperfusion injury drugs.     

Effect of RYR1 gene expression knock-down by siRNA on mitochondria in C2C12 cells

AIM: To investigate the effect of ryanodine receptor 1 (RYR1) down-regulation on mitochondria in mouse myoblast C2C12 cell line and to explore the possible mechanism. METHODS: The expression of RYR1 in the C2C12 cells was knocked down by the targeted small interfering RNA (siRNA). The mitochondrial number and morpholo-gical changes were evaluated by transmission electron microscopy and the stereoscopic analysis. Real-time PCR and Western blot were used to determine the mRNA and protein levels of mitofusin 2 (Mfn2), peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively. RESULTS: The expression of RYR1 was significantly down-regulated by siRNA transfection (P<0.01), with fragmentized mitochondria in the C2C12 cells in knock-down (KD) group. Although no statistical difference of the mitochondrial number was observed, the mitochondria area and circumference were significantly lowered in KD group (P<0.05). In KD group, the mRNA and protein expression of Mfn2 was significantly reduced (P<0.01). The mRNA level of PGC-1α was also reduced (P<0.01), but no significant change at protein level was observed. No change of ERK1/2 expression and phosphorylated ERK1/2 level was detected. CONCLUSION: Knock-down of RYR1 expression leads to morphological changes of mitochondria, and down-regulation of Mfn2 expression may be involved in the underlying mechanism. While PGC-1α and ERK1/2-associated oxidative stress pathway may not play an important role in the process.     

Effects of ERK1/2 on pressure overload-induced cardiomyopathy and heart failure in mice

AIM: To explore the changes in extracellular regulated protein kinase (ERK1/2) in the hypertrophic myocardium induced by pressure overload at the different time courses and to determine the molecular mechanism in the myocardium from hypertrophy to heart failure. METHODS: C57/BL mice, aged 12 week old, were subjected to sham-operation (SH) or transversing aortic constriction (TAC) to establish left ventricular hypertrophy. Echocardiographic assessments, hemodynamic determination, organ weight measurement, morphological and histological examination were performed at 1, 4, 8, 12 and 16 weeks after surgery. Meanwhile mRNA levels of atrial natriuretic peptide (ANP), α-myosin heavy chain (α-MHC), bcl-2 and bax were measured by RT-PCR, and ERK1/2 levels were detected by Western blotting. The animals in SH group were performed the same tests then sacrificed at 16 weeks. RESULTS: (1) Compared to SH group, LVESd, LVEDd, Awsth, Awdth, Pwsth and Pwdth progressively increased after TAC. Meanwhile, ejection fraction (EF%) significantly decreased at 16th week (P<0.05). LVSP, dp/dtmax and dp/dtmin in TAC group were progressively increased after 4 weeks. From 8-12 weeks these parameters maintained stable and then sharply decreased at 16th week (all P<0.05). However, LVEDP was statistically increased at 8th week. These echocardiographic and hemodynamic changes indicated a development of LVH and eventually progressing towards to heart failure. (2) Histologically, cardiac collagen measured by percentage of Sirius red positive stained area and apoptosis index showed progressive increases from 4 to 16 weeks. (3) Compared to SH group, mRNA levels of ANP was time-dependently increased while α-MHC and Bcl-2 were time-dependently decreased. The ratio of Bcl-2 /Bax was decreased. Phosphorylation of ERK1/2 was increased at 4th week, then decreased with age of TAC (all P<0.05). CONCLUSION: Pressure-overload induced by TAC results in a development of LVH from early concentric hypertrophy to late eccentric hypertrophy, and eventually toward cardiac dysfunction or heart failure. Those changes are associated with increase in cell size and cardiac fibrosis. ERK1/2 signaling pathway may involve in the regulation of myocardial cell apoptosis in hypertrophic and failure heart.     

Influence of Tangshenfang on diabetic liver injury and the expression of SIRT1 and PGC-1α in the liver tissue

AIM: To observe the effect of Tangshenfang (TS) on the liver protection and the levels of silent information regulator 1 (SIRT1) and peroxisom proliferator-activated receptor γ coactivator-1α (PGC-1α) in the liver tissue. METHODS: The rat model of diabetes mellitus (DM) was established by intravenous injection of streptozotocin (STZ;30 mg/kg) after having the high fat/high glucose diets for 1 month. The diabetic rats were randomly divided into DM group, DM with high-dose TS (TS^Hi) group, medium-dose TS (TS^Med) group and low-dose TS (TS^Low)group. The normal rats were served as control group. There were 8 rats in each group. After treatment with TS for 12 weeks, the serum biochemical indices including fasting blood glucose (FBG), triglyceride (TG), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were tested. Fasting insulin (FINS) was also detected by radioimmunoassay, and homeostatic model assessment for insulin resistance (HOMA-IR) was calculated. The serum levels of tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) were measured by ELISA. The activity of SOD and content of MDA in the liver tissues were measured by the methods of hydroxylamine and thiobarbituric acid. The liver pathological changes were observed under light microscope with HE and Masson staining. The protein expression of SIRT1and PGC-1α in the liver tissues was determined by Western blot. RESULTS: In DM group, serum FBG, TG, ALT, AST, FINS, HOMA-IR, TNF-α and IL-1 were obviously increased compared with the control group (P<0.01). The fatty changes, local necrosis, inflammation and fibrosis in the liver tissues were observed. The content of MDA in liver increased, while the activity of SOD decreased markedly. The protein expression of SIRT1 and PGC-1α was decreased (P<0.05). In TS treatment groups, all these changes in DM rats were markedly reversed by TS, and the protein expression of SIRT1 and PGC-1α in the liver tissues was markedly increased. CONCLUSION: TS may protect the rats from diabetic liver injury by increasing the expression of SIRT1 and PGC-1α, and thereby improving insulin resistance and oxidative stress.     

Effects of PPARβ and NO on high glucose and insulin-induced cardiomyocyte hypertrophy

AIM: To investigate the role of peroxisome proliferator-activated receptor β(PPARβ)-nitric oxide(NO) signal pathway in cardiomyocyte hypertrophy induced by high glucose(25.5 mmol/L) and insulin(0.1 μmol/L)(HGI). METHODS: The cardiomyocyte hypertrophy was characterized in rat primary cardiomyocytes by measuring the cell surface area, protein content, and the mRNA expression of atrial natriuretic factor(ANF). The mRNA and protein expression were measured by real-time PCR and Western blotting, respectively. The activity of NO synthase(NOS) and NO content were measured by a reagent kit through ultraviolet spectroscopy. RESULTS: HGI induced profound change of hypertrophic morphology, and significantly increased the cell surface area, protein content and mRNA expression of ANF(P<0.01), but decreased the expression of PPARβ at mRNA and protein levels(P<0.05). At the same time, the expression of inducible NOS(iNOS) was obviously elevated(P<0.01), which occurred in parallel with the rising NOS activity and NO concentration(P<0.01). GW0742(1 μmol/L), a selective PPARβ agonist, inhibited the cardiomyocyte hypertrophy induced by HGI(P<0.01), and up-regulated the expression of PPARβ at both mRNA and protein levels. Meanwhile, GW0742 also inhibited the increases in iNOS expression, NOS activity, and NO content induced by HGI, which were abolished by GSK0660(1 μmol/L), a selective PPARβ antagonist(P<0.01). CONCLUSION: PPARβ down-regulation and the following iNOS-NO activation are involved in the cardiomyocyte hypertrophy induced by HGI.     

Artesunate negatively controls expression of cyclin D1 and activity of AP-1 by inhibiting the activation of ERK1/2 protein in HSC-T6 cells

AIM: To investigate the effects of artesunate(Art) on the expression of ERK1/2, AP-1 and cyclin D1 in rat hepatic stellate cells (HSCs), and to elucidate the molecular mechanism of Art against hepatic fibrosis. METHODS: HSC-T6 cells were treated with platelet-derived growth factor BB(PDGF-BB) to induce cell proliferation. The cells were divided into control group, PDGF-BB group, PDGF-BB+Art groups (with 6.25 mg稬^-1, 25 mg稬^-1or 50 mg稬^-1 of Art) and PDGF-BB+PD98059 group. The level of collagen type I in the supernatant was detected by enzyme-linked immunosorbent assay (ELISA). The mRNA expression levels of ERK1/2 and cyclin D1 were measured by RT-PCR. The protein levels of p-ERK1/2 and cyclin D1 in HSC-T6 cells were detected by Western blotting. The activity of AP-1 was analyzed by electrophoretic mobility shift assay. RESULTS: The concentration of collagen type I was significantly higher in PDGF-BB group than that in control group (P<0.05), and decreased in PDGF-BB+Art group and PDGF-BB+PD98059 group in comparison with that in PDGF-BB group (P<0.05, P<0.01). The protein level of ERK1/2 in PDGF-BB+Art group (50 mg稬^-1) was lower than that in PDGF-BB group (P<0.05), and was even lower in PDGF-BB+PD98059 group (P<0.01). The mRNA expression of cyclin D1 in PDGF-BB+Art groups (25 mg稬^-1and 50 mg稬^-1) and PDGF-BB+PD98059 group were significantly lower than that in PDGF-BB group (P<0.05). The protein levels of p-ERK1/2 and cyclinD1 were the highest in PDGF-BB group, and significantly lower in PDGF-BB+Art groups (6.25 mg稬^-1, 25 mg稬^-1 and 50 mg稬^-1) and PDGF-BB+PD98059 group (P<0.05, P<0.01). The AP-1 binding activity in HSC-T6 cells was down-regulated by Art. CONCLUSION: Artesunate inhibits the proliferation of HSC-T6 cells in vitro by inhibiting the activation of ERK1/2, thus down-regulating the activity of AP-1 and expression of cyclin D1.     

Erk1/2 MAP kinase mediates function of FGF21 to regulate hepatic lipid metabolism

AIM: To investigate whether attenuation of extracellular signal-regulated kinase 1/2 (Erk1/2), an MAP kinase, will affect the regulatory function of fibroblast growth factor 21 (FGF21) on hepatic lipid metabolism. METHODS: Male C57BL/6J wild-type (WT) mice (8 weeks old) were fed with high-fat diet (HFD) for 4 weeks, and then treated with U0126 (an MEK inhibitor, inactivating Erk1/2) and/or adeno-associated virus-FGF21 (AAV-FGF21) for 4 weeks. The change of hepatic lipid profiles and its relevant regulatory genes were evaluated. Meanwhile, the molecular mechanism was explored by in vitro study. RESULTS: Treatment with AAV-FGF21 significantly reduced serum trigly-ceride and total cholesterol levels in the HFD-fed WT mice. Moreover, AAV-FGF21 administration significantly decreased the expression of lipogenic regulatory gene Srebp-2, largely increased the expression of relevant genes including Acacb, ABCG5 and Cyp7a1, which were involved in fatty acid oxidation, cholesterol transport and bile acid production, and strongly inhibited the expression of hepatic inflammatory factors such as IL-1β, MCP-1 and TNF-α in the mice. However, these beneficial effects caused by AAV-FGF21 were strongly attenuated by U0126. On the other hand, in vitro experiments indicated that treatment with recombinant human FGF21 protein significantly down-regulated Srebp-2 expression at mRNA and protein levels in a dose- and time-dependent manner. These effects were abolished after U0126 administration. CONCLUSION: FGF21 improves the lipid metabolism in the liver, and Erk1/2 signaling partially regulates these biological effects of FGF21.     

Changes of liver lipid metabolism-related PPAR-γ/LXR-α/ABCG1 pathways and inflammatory factors in atherosclerotic mice and role of Huayu-Qutan recipe

AIM To observe the changes of liver lipid metabolism-related peroxisome proliferator-activated receptor-γ (PPAR-γ)/liver X receptor-α (LXR-α)/ATP-binding cassette transporter G1 (ABCG1) signaling pathways and inflammatory factors in mice with atherosclerosis (AS), and to investigate the effects of Huayu-Qutan recipe (HYQT) on hepatic lipid metabolism and inflammatory response and the mechanisms. METHODS ApoE^-/- mice (n=24) were randomly divided into model group, HYQT group and simvastatin group, and C57BL/6J mice (n=8) were used as control group. Except for the control group, the mice in other groups were given high-fat diet. After 12 weeks of modeling, the mice in HYQT and simvastatin groups were intragastrically given the corresponding drugs, and the mice in control and model groups were given the same volume of normal saline. After 8 weeks, the serum levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured by an automatic biochemical analyzer. HE and oil red O staining was used to observe liver histopathological and lipid changes. The hepatic levels of free fatty acid (FFA), TG, tumor necrosis factor-α (TNF-α), Toll-like receptor 4 (TLR4) and interleukin-1β (IL-1β) were detected by ELISA. The protein expression of PPAR-γ, LXR-α and ABCG1 was determined by Western blot. RESULTS Compared with control group, the serum levels of TC, TG and LDL-C in model group were significantly increased (P<0.01), and the HDL-C content was significantly decreased (P<0.01). Liver steatosis, cell size augmentation and lipid deposition were obvious, and liver FFA and TG levels were significantly increased (P<0.01). The liver levels of TLR4, TNF-α and IL-1β were significantly increased (P<0.01), while the protein expression of PPAR-γ, LXR-α and ABCG1 was significantly decreased (P<0.05 or P<0.01). Compared with model group, the serum levels of TC, TG and LDL-C in simvastatin group and HYQT group were significantly decreased (P<0.05 or P<0.01), and the HDL-C content was significantly increased (P<0.01). Liver steatosis was weakened, and liver lipid deposition and FFA and TG levels were significantly decreased (P<0.05 or P<0.01). The liver levels of TLR4, TNF-α and IL-1β were significantly decreased (P<0.01), while the protein expression of PPAR-γ, LXR-α and ABCG1 was significantly increased (P<0.05 or P<0.01). CONCLUSION Huayu-Qutan recipe may exert anti-AS effect by regulating liver PPAR-γ/LXR-α/ABCG1 pathways and attenuating liver TRL4-mediated inflammatory responses.     

Effect of rosiglitazone on expression of AQP1, VEGF-A and COX-2 in human peritoneal microvascular endothelial cells

AIM: To investigate the effect of rosiglitazone on the expression of aquaporin-1 (AQP1), vascular endothelial growth factor-A (VEGF-A) and cyclooxygenase-2 (COX-2) in human peritoneal microvascular endothelial cells.METHODS: Cultured peritoneal microvascular endothelial cells were divided into 4 groups. The morphological changes of the cells were observed under inverted microscope. The protein expression of AQP1, VEGF-A and COX-2 in human peritoneal microvascular endothelial cells was determined by Western blotting. The mRNA expression of AQP1, VEGF-A and COX-2 in the cells was measured by real-time PCR. RESULTS: Rosiglitazone stimulated the proliferation of the cells. Rosiglitazone up-regulated the expression of AQP1, and down-regulated the expression of VEGF-2 and COX-2 at mRNA and protein levels in the cells. The PPAR-γ antagonist GW9662 partly inhibited the up-regulation of AQP1 expression by rosiglitazone (P<0.05), but had no obvious effect on the expression of VEGF-A and COX-2 (P>0.05). CONCLUSION: Rosiglitazone up-regulates the expression of AQP1 and down-regulates the expression of VEGF-A and COX-2 in human peritoneal microvascular endothelial cells, thus promoting water transportation and attenuating peritoneal fibrosis during peritoneal dialysis.     

Effects of several harmful factors on expression of glycine receptor α1 subunit in neonatal rat myocardial cells

AIM: To study the expression of glycine receptor α₁ subunit in neonatal rat myocardial cells and to investigate the effect of lipopolysaccharide (LPS), hypoxia/reoxygenation, isoproterenol (ISO) and high concentration of glucose (HG) on the expression of glycine receptor α₁ subunit in the neonatal rat myocardial cells. METHODS: Neonatal rat myocardial cells were cultured in vitro. The expression of glycine receptor α₁ subunit was detected by Western blotting. The neonatal rat myocardial cells were treated with LPS (20 mg/L), ISO (100μmol/L) or high concentration of glucose (25 mmol/L) for 24 h, or were exposed to hypoxia for 3 h followed by reoxygenation for 3 h. Subsequently, the cell viability was measured by CCK-8 assay, and the expression of glycine receptor α₁ subunit was determined by Western blotting. RESULTS: The expression of glycine receptor α₁ subunit in the neonatal rat myocardial cells was positively detectable by Western blotting. Compared with control group, no significant difference of the cell viability (P>0.05) in LPS group, ISO group, hypoxia/reoxygenation group and HG group was observed. The expression of glycine receptor α₁ subunit was increased (P<0.01) in LPS group, ISO group and hypoxia/reoxygenatio group, but decreased (P<0.01) in HG group. CONCLUSION: Glycine receptor α₁ subunit exists in the neonatal rat myocardial cells. A certain concentration of LPS or ISO, or hypoxia/reoxygenation for a certain period upregulate the expression of glycine receptor α₁ subunit, but HG downregulates the expression of glycine receptor α₁ subunit in cultured neonatal rat myocardial cells.     

Effects of Danshensu on TGF-β1/Smads signaling pathways in rats with pulmonary fibrosis

AIM: To study the preventive and curative roles of Danshensu (DA) in bleomycin (BLM)-induced pulmonary fibrosis in rats. METHODS: Pulmonary fibrosis was induced in SD rats by intratracheal instillation of BLM. The rats were intraperitoneally injected with dexamethasone (1 mg·kg-1·d-1, DXM group), DA (15 mg·kg-1·d-1, DA group), or physiological saline (2 mL·d-1, BLM group). Normal controls (NC group) received physiological saline both intratracheally and intraperitoneally. At the 28th day after modeling, the histological changes of the lungs were evaluated by hematoxylin-eosin (HE) and Masson’s trichrome staining. The protein levels of α-smooth muscle actin (α-SMA) in the lung tissues were detected by the method of immunohistochemistry. The mRNA expression of transforming growth factor beta 1 (TGF-β1), Smad3 and Smad7 was assessed by real-time fluorescence quantitative PCR. RESULTS: Compared with BLM group, the degree of inflammation and fibrosis of the lung in DA group was obviously reduced, and so was the expression of α-SMA in the lung tissues. The mRNA expression of TGF-β1 and Smad3 in the lung tissues of the rats decreased and the mRNA expression of Smad7 increased. CONCLUSION: DA alleviates BLM-induced pulmonary fibrosis in rats in the early stage by inhibiting the expression of TGF-β1/Smad3 and stimulating the expression of Smad7 in the lung tissues.     

Pharmaceutical inactivation of Erk1/2 does not affect function of FGF21 to regulate glucose and lipid metabolic hemostasis

AIM: To investigate whether inactivation of extracellular signal-regulated kinase 1/2 (Erk1/2) will affect the function of fibroblast growth factor 21 (FGF21) to regulate glucose and lipid metabolism. METHODS: Male db/db mice (8 weeks old) were treated with U0126 (an inhibitor of Erk1/2 kinase) for 1 week, and then treated with recombinant human FGF21 protein and adenovirus-mediated FGF21 (Ad-FGF21). The profile changes of blood glucose and blood lipid were evaluated at 120 min or 4 weeks after FGF21 administration. Meanwhile, the molecular mechanism was explored by in vitro study. RESULTS: Treatment of db/db mice with recombinant human FGF21 protein significantly reduced blood glucose and triglyceride levels at 120 min after FGF21 administration, but these changes were comparable in U0126-treated mice. Furthermore, abnormal glucose and triglyceride levels, and glucose and insulin tolerance were strongly improved in db/db mice as accompanied with decreasing body fat content after 4 weeks of ad-FGF21 administration. Interestingly, treatment with or without U0126 did not influence these effects of FGF21. Mechanically, treatment with Ad-FGF21 significantly upregulated the protein levels of p-Erk1/2 and peroxisome proliferator-activated receptor γ (PPARγ) as well as the expression of adiponectin at mRNA and protein levels in adipose tissues. However, treatment with or without U0126 did not change the profiles. On the other hand, in vitro experiments also indicated that treatment of adipocytes with recombinant human FGF21 protein significantly activated Erk1/2 phosphorylation, and upregulated the expression levels of PPARγ and adiponectin (P<0.05). However, pre-administration of U0126 did not affect the profiles. CONCLUSION: Pharmaceutical inactivation of Erk1/2 by U0216 does not affect the biological function of FGF21 to regulate blood glucose balance and improve abnormal blood lipids in vivo.     

β-estradiol promotes invasion and migration of lung cancer A549 cells via ERβ-mediated ERK1/2 membrane-initiated steroid signaling

AIM: To investigate the regulatory mechanism of β-estradiol in the invasion and migration of lung cancer A549 cells. METHODS: Breast cancer MCF-7 cells and lung cancer A549 cells were cultured in vitro. The MCF-7 cells were used as the estrogen receptor (ER) positive expression cell model. Real-time PCR and immunofluorescence were employed to measure the expression level and the localization of ER in A549 cells. The phosphorylation of ERK1/2 upon β-estradiol stimulation was quantified by Western blot. The invasion and migration abilities of A549 cells upon β-estradiol stimulation with or without ERK1/2 inhibitor PD98059 were measured by Transwell and Cell-IQ assays. RESULTS: ERβ was the dominant ER subtype in the A549 cells and primarily comprised of ERβ2 and ERβ5. Immunofluorescence revealed that ERβ expression was mainly localized in the cytoplasm. β-estradiol induced phosphorylation of ERK1/2 and promoted the invasion and migration of the cells. Inhibition of ERK1/2 signaling reversed β-estradiol-promoted invasion and migration of A549 cells. CONCLUSION: ERβ-mediated membrane-initiated steroid signaling is involved in the process of β-estradiol-promoted invasion and migration of A549 cells, through which ERK1/2 signaling plays a pivotal role.     

Effect of eleutheroside B/E on proliferation and expression of PPARγ and TGF-β1 in HBZY-1 cells cultured with high glucose

AIM: To explore the effects and mechanism of eleutheroside (ETS) B or E on the proliferation of HBZY-1 cells treated with high glucose. METHODS: The HBZY-1 cells were cultured under high glucose condition. The 4th generation of HBZY-1 cells was used for determining the optimal cell density, which was consistent with the growth regulation curve of the cells. The cells were divided into 6 groups: low glucose (LG) group, high glucose (HG) group, high glucose plus ETS-B/E (low dose, medium dose and high dose) groups, and high glucose plus losartan (LTG) group. After all cells were treated with the corresponding drugs at 24 h, 48 h and 72 h, the inhibitory rate of the proliferation was measured, and the expression of TGF-β1 and PPARγ was detected by immunocytochemistry and Western blotting. RESULTS: The best cell density was 2 000 cells/well, which was complied with the basic rules of the cell growth, and high glucose significantly promoted the HBZY-1 cell proliferation. At each time point, the inhibitory effects of ETS-B/E were significantly different between HG group and LTG group on the proliferation of the HBZY-1 cells (P<0.05). The expression of TGF-β1 was significantly inhibited, and the expression of PPARγ was significantly promoted by ETS-B/E (P<0.05). ETS-E showed stronger effect than ETS-B (P<0.05) in a concentration- and time-dependent manner. CONCLUSION: ETS-B/E significantly inhibits the proliferation of HBZY-1 cells under high glucose condition by decreasing TGF-β1 expression and promoting PPARγ expression.